Safety, Efficacy and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03.

Xinan ShengHaige ChenBin HuXudong YaoZiling LiuXin YaoHongqian GuoYi HuZhigang JiHong LuoBenkang ShiZhenhua LiuJin WuFangJian ZhouZhisong HeJinhai FanWeifeng WangHui FengSheng YaoPatricia KeeganYiran HuangJun Guo

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Toripalimab has demonstrated encouraging clinical activity in the second-line treatment of mUC with a manageable safety profile. PD-L1 expression and TMB were two independent biomarkers in the study.

Keyphrases

open label
cross sectional
randomized controlled trial
replacement therapy